Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cuprina Holdings (Cayman) Limited Class A ( (CUPR) ) has provided an announcement.
On July 21, 2025, Cuprina Holdings announced the appointment of Dr. Ronald A. Sherman as Medical and Scientific Director, effective September 15, 2025. The company also signed a licensing agreement with Dr. Sherman for the FDA-approved Lucilia sericata Medical Maggots, marking a significant step in expanding their maggot debridement therapy offerings in the U.S. market. This strategic move is expected to enhance Cuprina’s clinical expertise and regulatory capabilities, potentially increasing the adoption of minimally invasive wound care techniques globally.
More about Cuprina Holdings (Cayman) Limited Class A
Cuprina Holdings (Cayman) Limited is a Singapore-based biomedical and biotechnology company focused on developing and commercializing products for chronic wound management and the health and beauty sectors. The company specializes in utilizing natural materials to create wound care products that meet international standards.
Average Trading Volume: 209,641
Learn more about CUPR stock on TipRanks’ Stock Analysis page.